Introduction

Managing gout in patients with end-stage renal disease (ESRD) on peritoneal dialysis (PD) presents a significant clinical hurdle. Conventional therapies, including nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, often prove risky or ineffective due to the patient's underlying comorbidities. Consequently, clinicians are investigating advanced biological therapies like Firsekibart for acute gout to provide safer, more effective outcomes for high-risk individuals.

Case Report: Managing Refractory Symptoms

A recent case report detailed a 52-year-old female PD patient suffering from recurrent joint swelling and intense pain. Despite undergoing standard treatments, her condition remained refractory. Her medical history was complicated by heart failure, recurrent pulmonary infections, and severe anemia. Laboratory investigations confirmed a high inflammatory state with a C-reactive protein (CRP) of 16.6 mg/L and serum uric acid (UA) of 627 μmol/L.

The Role of Firsekibart for Acute Gout

Due to the failure of conventional agents, the patient received a single 200 mg dose of Firsekibart. This IL-1β monoclonal antibody target specifically addresses the inflammatory cascade of gout. Remarkably, joint pain and swelling improved significantly within just 24 hours. The patient’s Visual Analogue Scale (VAS) score dropped from 5 to 1 within three days. Additionally, her CRP levels decreased to 6.5 mg/L by day 3, and her uric acid levels stabilized without significant adverse effects. Notably, a seven-month follow-up revealed no recurrence of acute attacks, suggesting long-term benefits.

Clinical Significance and Safety

This case demonstrates that IL-1β blockade can be a game-changer for ESRD patients. Firsekibart provided rapid relief without the typical renal or systemic toxicity associated with older medications. Furthermore, the absence of injection site reactions or hypersensitivity during the follow-up period underscores its potential safety profile. For specialists managing complex gout in dialysis patients, these findings suggest a promising alternative when first-line therapies fail.

Frequently Asked Questions

What is Firsekibart and how does it work?

Firsekibart is a monoclonal antibody that targets interleukin-1 beta (IL-1β). By neutralizing this specific cytokine, it stops the intense inflammatory response responsible for the pain and swelling seen in acute gout flares.

Why is Firsekibart preferred over NSAIDs in dialysis patients?

Dialysis patients often have multiple comorbidities like heart failure and gastrointestinal risks that contraindicate the use of NSAIDs. Firsekibart offers a targeted anti-inflammatory effect without the systemic risks associated with traditional anti-inflammatory drugs.

Is Firsekibart effective for long-term gout management?

While primarily used for acute flares, this case study showed that a single dose could prevent recurrence for up to seven months. However, it is usually part of a broader strategy that includes urate-lowering therapy for long-term control.

Disclaimer: This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Wei W et al. Acute gout attack in a peritoneal dialysis patient treated with Firsekibart: a case report. Open Med (Wars). 2026 Jan undefined. doi: 10.1515/med-2026-1454. PMID: 42239734.

Xue Y et al. Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial. The Innovation. 2025.

Tan X et al. Firsekibart for steroid withdrawal in glucocorticoid-dependent refractory gout: a case report. Front Immunol. 2026.